Aytu reports strong prescription growth for Natesto low-T drug

Aytu reports strong prescription growth for Natesto low-T drug

ENGLEWOOD -- Aytu BioScience, Inc . (OTCQX: AYTUD), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that through... Read More

Tuesday September 26, 2017 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Natesto

Aytu BioScience announces subscriptions for $11.5M to fund Natesto, operations

Aytu BioScience announces subscriptions for $11.5M to fund Natesto, operations

ENGLEWOOD -- Aytu BioScience, Inc . (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced it received... Read More

Monday August 14, 2017 0 comments Tags: Aytu BioScience, Englewood, Natesto

Aytu BioScience sells Primsol to Allegis Holdings

Aytu BioScience sells Primsol to Allegis Holdings

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced the divestiture of... Read More

Tuesday April 4, 2017 0 comments Tags: Englewood, Aytu BioScience, Allegis Holdings, Josh Disbrow, Natesto, MiOXSYS

Aytu BioScience expands sales team to support growth of Natesto

Aytu BioScience expands sales team to support growth of Natesto

ENGLEWOOD -- Aytu BioScience, Inc . (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the expansion... Read More

Wednesday February 22, 2017 0 comments Tags: Englewood, Aytu BioScience, Natesto, Josh Disbrow

Aytu BioScience announces $10.5M stock agreement

Aytu BioScience announces $10.5M stock agreement

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced it has entered... Read More

Thursday July 28, 2016 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Natesto

Aytu BioScience provides update on Natesto launch

Aytu BioScience provides update on Natesto launch

ENGLEWOOD -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced an update on the... Read More

Wednesday July 6, 2016 0 comments Tags: Englewood, Aytu BioScience, Natesto, Acerus Pharma, Jonathan McGrael, Josh Disbrow

Aytu BioScience offering 18.75M shares to raise $7.5M

Aytu BioScience offering 18.75M shares to raise $7.5M

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced it has priced an... Read More

Tuesday May 3, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, MiOXSYS, ProstaScint, Primsol

Aytu Bioscience acquires rights to Natesto drug

Aytu Bioscience acquires rights to Natesto drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the exclusive licensing... Read More

Monday April 25, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, Acerus Pharma, Josh Disbrow, Tom Rossi